A 2020 case series of three patients with Rituximab-refractory PLA2R-associated membranous nephropathy demonstrated complete immunological remission in all three patients followed by partial clinical remission in two [11]. The gene discussed is PLA2R1; the disease is membranous glomerulonephritis.